Milton Packer
Cardiovascular Disease · Dallas, TXNPI 1083588552
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $522,745 of the $529,588 with a category attached, or 98.7%. Eli Lilly accounts for 92.5% of it on its own, with 5 other manufacturers making up the rest. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $22,066 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eli Lilly$490K
- Novo Nordisk$24K
- Novo Nordisk AS$11K
- Amgen$5K
- Regeneron$991
- Medtronic$37
What the payments were for
- Consulting fees$522,74599%
- Travel & lodging$6,5581%
- Food & beverage$2850%
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eli Lilly | 12 | $489,917 |
| Novo Nordisk | 6 | $23,519 |
| Novo Nordisk AS | 3 | $10,600 |
| Amgen | 1 | $4,524 |
| Regeneron | 1 | $991 |
| Medtronic | 1 | $37 |
How this compares
$529,588 in reported general payments places this provider in the 95th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Dallas
- Ramin Farzaneh-FarDallas$17.1M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Amarinder BindraDallas$512K
- Ambarish PandeyDallas$325K
- Eric PetersonDallas$187K
- Brittany WeberDallas$186K
- James de LemosDallas$181K
- Subhash BanerjeeDallas$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.